NPM1 and myeloproliferative disorder: Bains et al. documented FLT3 and NPM1 mutations in 2% and 4.4% of cases, respectively, from a large cohort of non-acute MNs, with NPM1 mutations being significantly associated with normal karyotype and higher risk MDS or MDS/MPN [62].